Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 149Breast Neoplasms 87Colorectal Neoplasms 64Neoplasms 53Pancreatic Neoplasms 52Lung Neoplasms 49Neoplasm Metastasis 45Stomach Neoplasms 43Ovarian Neoplasms 42Rectal Neoplasms 41Esophageal Squamous Cell Carcinoma 34Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 30Head and Neck Neoplasms 30Leukemia, Myeloid, Acute 28Recurrence 24Triple Negative Breast Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Glioblastoma 21Uterine Cervical Neoplasms 20Small Cell Lung Carcinoma 20Nasopharyngeal Carcinoma 20Fallopian Tube Neoplasms 19Lymphoma, Non-Hodgkin 18Lymphoma 18Colonic Neoplasms 17Prostatic Neoplasms 16Leukemia 15Carcinoma, Ovarian Epithelial 15Melanoma 14

Interventions

Bevacizumab 5pembrolizumab 4Gemcitabine 4Cisplatin 4napabucasin 3Paclitaxel 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3entinostat 2anlotinib 2Taxes 2Sunitinib 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Leucovorin 2Immunotherapy 2Fluorouracil 2Carboplatin 2sipuleucel-T 1pralsetinib 1palbociclib 1olaparib 1niraparib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1ixabepilone 1interferon gamma-1b 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Glandular and Epithelial × Drug Therapy × Clear all
NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡